Cargando…
A metabolism-associated gene signature for prognosis prediction of hepatocellular carcinoma
Hepatocellular carcinoma (HCC), the most frequently occurring type of cancer, is strongly associated with metabolic disorders. In this study, we aimed to characterize the metabolic features of HCC and normal tissue adjacent to the tumor (NAT). By using samples from The Cancer Genome Atlas (TCGA) liv...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561844/ https://www.ncbi.nlm.nih.gov/pubmed/36250026 http://dx.doi.org/10.3389/fmolb.2022.988323 |
_version_ | 1784808036454367232 |
---|---|
author | Tian, Yilin Lu, Jing Qiao, Yongxia |
author_facet | Tian, Yilin Lu, Jing Qiao, Yongxia |
author_sort | Tian, Yilin |
collection | PubMed |
description | Hepatocellular carcinoma (HCC), the most frequently occurring type of cancer, is strongly associated with metabolic disorders. In this study, we aimed to characterize the metabolic features of HCC and normal tissue adjacent to the tumor (NAT). By using samples from The Cancer Genome Atlas (TCGA) liver cancer cohort and comparing 85 well-defined metabolic pathways obtained from the Kyoto Encyclopedia of Genes and Genomes (KEGG), 70 and 7 pathways were found to be significantly downregulated and upregulated, respectively, in HCC, revealing that tumor tissue lacks the ability to maintain normal metabolic levels. Through unsupervised hierarchical clustering of metabolic pathways, we found that metabolic heterogeneity correlated with prognosis in HCC samples. Thus, using the least absolute shrinkage and selection operator (LASSO) and filtering independent prognostic genes by the Cox proportional hazards model, a six-gene-based metabolic score model was constructed to enable HCC classification. This model showed that high expression of LDHA and CHAC2 was associated with an unfavorable prognosis but that high ADPGK, GOT2, MTHFS, and FTCD expression was associated with a favorable prognosis. Patients with higher metabolic scores had poor prognoses (p value = 2.19e-11, hazard ratio = 3.767, 95% CI = 2.555–5.555). By associating the score level with clinical features and genomic alterations, it was found that NAT had the lowest metabolic score and HCC with tumor stage III/IV the highest. qRT‒PCR results for HCC patients also revealed that tumor samples had higher score levels than NAT. Regarding genetic alterations, patients with higher metabolic scores had more TP53 gene mutations than those with lower metabolic scores (p value = 8.383e-05). Validation of this metabolic score model was performed using another two independent HCC cohorts from the Gene Expression Omnibus (GEO) repository and other TCGA datasets and achieved good performance, suggesting that this model may be used as a reliable tool for predicting the prognosis of HCC patients. |
format | Online Article Text |
id | pubmed-9561844 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95618442022-10-15 A metabolism-associated gene signature for prognosis prediction of hepatocellular carcinoma Tian, Yilin Lu, Jing Qiao, Yongxia Front Mol Biosci Molecular Biosciences Hepatocellular carcinoma (HCC), the most frequently occurring type of cancer, is strongly associated with metabolic disorders. In this study, we aimed to characterize the metabolic features of HCC and normal tissue adjacent to the tumor (NAT). By using samples from The Cancer Genome Atlas (TCGA) liver cancer cohort and comparing 85 well-defined metabolic pathways obtained from the Kyoto Encyclopedia of Genes and Genomes (KEGG), 70 and 7 pathways were found to be significantly downregulated and upregulated, respectively, in HCC, revealing that tumor tissue lacks the ability to maintain normal metabolic levels. Through unsupervised hierarchical clustering of metabolic pathways, we found that metabolic heterogeneity correlated with prognosis in HCC samples. Thus, using the least absolute shrinkage and selection operator (LASSO) and filtering independent prognostic genes by the Cox proportional hazards model, a six-gene-based metabolic score model was constructed to enable HCC classification. This model showed that high expression of LDHA and CHAC2 was associated with an unfavorable prognosis but that high ADPGK, GOT2, MTHFS, and FTCD expression was associated with a favorable prognosis. Patients with higher metabolic scores had poor prognoses (p value = 2.19e-11, hazard ratio = 3.767, 95% CI = 2.555–5.555). By associating the score level with clinical features and genomic alterations, it was found that NAT had the lowest metabolic score and HCC with tumor stage III/IV the highest. qRT‒PCR results for HCC patients also revealed that tumor samples had higher score levels than NAT. Regarding genetic alterations, patients with higher metabolic scores had more TP53 gene mutations than those with lower metabolic scores (p value = 8.383e-05). Validation of this metabolic score model was performed using another two independent HCC cohorts from the Gene Expression Omnibus (GEO) repository and other TCGA datasets and achieved good performance, suggesting that this model may be used as a reliable tool for predicting the prognosis of HCC patients. Frontiers Media S.A. 2022-09-30 /pmc/articles/PMC9561844/ /pubmed/36250026 http://dx.doi.org/10.3389/fmolb.2022.988323 Text en Copyright © 2022 Tian, Lu and Qiao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Molecular Biosciences Tian, Yilin Lu, Jing Qiao, Yongxia A metabolism-associated gene signature for prognosis prediction of hepatocellular carcinoma |
title | A metabolism-associated gene signature for prognosis prediction of hepatocellular carcinoma |
title_full | A metabolism-associated gene signature for prognosis prediction of hepatocellular carcinoma |
title_fullStr | A metabolism-associated gene signature for prognosis prediction of hepatocellular carcinoma |
title_full_unstemmed | A metabolism-associated gene signature for prognosis prediction of hepatocellular carcinoma |
title_short | A metabolism-associated gene signature for prognosis prediction of hepatocellular carcinoma |
title_sort | metabolism-associated gene signature for prognosis prediction of hepatocellular carcinoma |
topic | Molecular Biosciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561844/ https://www.ncbi.nlm.nih.gov/pubmed/36250026 http://dx.doi.org/10.3389/fmolb.2022.988323 |
work_keys_str_mv | AT tianyilin ametabolismassociatedgenesignatureforprognosispredictionofhepatocellularcarcinoma AT lujing ametabolismassociatedgenesignatureforprognosispredictionofhepatocellularcarcinoma AT qiaoyongxia ametabolismassociatedgenesignatureforprognosispredictionofhepatocellularcarcinoma AT tianyilin metabolismassociatedgenesignatureforprognosispredictionofhepatocellularcarcinoma AT lujing metabolismassociatedgenesignatureforprognosispredictionofhepatocellularcarcinoma AT qiaoyongxia metabolismassociatedgenesignatureforprognosispredictionofhepatocellularcarcinoma |